258 results match your criteria: "Centre expert Dépression résistante FondaMental[Affiliation]"

Article Synopsis
  • Clinical heterogeneity in bipolar disorder (BD) refers to the diverse experiences of individuals with the same diagnosis, affecting their remission and recovery during periods of wellbeing known as euthymia.
  • A study with 58 participants identified five distinct profiles of experiences during euthymia, based on their symptoms and recovery, and highlighted that current family functioning plays a significant role in these experiences.
  • The findings suggest that understanding personal recovery and family dynamics is crucial for clinicians to adapt their care strategies effectively for individuals with BD.
View Article and Find Full Text PDF

Neuroimaging correlates of cognitive disorders secondary to electroconvulsive therapy: A systematic review.

Encephale

November 2024

Service de Psychiatrie et de Psychologie Médicale (Department of Psychiatry and Medical Psychology), Centre Expert Dépression Résistante FondaMental, Hôpital Purpan, CHU de Toulouse, Toulouse, France; Inserm, UPS, Toulouse NeuroImaging Centre (ToNIC), Université de Toulouse, Toulouse, France. Electronic address:

Objectives: Electroconvulsive therapy is known as an efficient therapy, which is sometimes recommended for the management of severe and resistant depression. However, ECT is associated with cognitive adverse effects. The study of the neurobiological correlates of the cognitive adverse effects of ECT has been covered in few published reviews.

View Article and Find Full Text PDF

Refining Criteria for a Neurodevelopmental Subphenotype of Bipolar Disorders: A FondaMental Advanced Centers of Expertise for Bipolar Disorders Study.

Biol Psychiatry

October 2024

Fondation Fondamental, Créteil, France; Centre Hospitalier Universitaire de Montpellier, Hôpital Lapeyronie, Psychiatric Emergency and Post Emergency Department, Pole Urgence, Montpellier, France; L'Institut de Génomique Fonctionnelle, Université de Montpellier, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Montpellier, France. Electronic address:

Article Synopsis
  • Bipolar disorder (BD) is a complex mental health condition, and researchers aimed to identify a neurodevelopmental phenotype (NDP) that contributes to its development and impacts clinical outcomes.
  • By analyzing data from over 4,400 BD patients, they established nine specific clinical features that characterize this NDP, which are linked to poorer prognosis and treatment responses.
  • The findings suggest that patients with a higher NDP load may have overlapping genetic factors with ADHD, indicating a potential shared biological basis for these disorders.
View Article and Find Full Text PDF

The Global ECT MRI Research Collaboration (GEMRIC) has collected clinical and neuroimaging data of patients treated with electroconvulsive therapy (ECT) from around the world. Results to date have focused on neuroimaging correlates of antidepressant response. GEMRIC sites have also collected longitudinal cognitive data.

View Article and Find Full Text PDF

Diet quality and associations with lactate and metabolic syndrome in bipolar disorder.

J Affect Disord

November 2024

Department of Pharmacology and Toxicology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Mitochondrial Innovation Initiative, MITO2i, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada. Electronic address:

Background: Nutrition is largely affected in bipolar disorder (BD), however, there is a lack of understanding on the relationship between dietary categories, BD, and the prevalence of metabolic syndrome. The objective of this study is to examine dietary trends in BD and it is hypothesized that diets with increased consumption of seafood and high-fiber carbohydrates will be correlated to improved patient outcomes, and a lower frequency of metabolic syndrome.

Methods: This retrospective cohort study includes two French cohorts.

View Article and Find Full Text PDF

Sub-optimal response in schizophrenia is frequent, warranting augmentation strategies over treatment-as-usual (TAU). We assessed nutraceuticals/phytoceutical augmentation strategies via network meta-analysis. Randomized controlled trials in schizophrenia/schizoaffective disorder were identified via the following databases: PubMed, MEDLINE, EMBASE, Scopus, PsycINFO, CENTRAL, and ClinicalTrials.

View Article and Find Full Text PDF

Mitochondrial Biomarkers and Metabolic Syndrome in Bipolar Disorder.

Psychiatry Res

September 2024

Department of Pharmacology and Toxicology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Mitochondrial Innovation Initiative, MITO2i, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.

Article Synopsis
  • This study investigates the link between mitochondrial blood biomarkers, specifically lactate and circulating cell-free mitochondrial DNA, and markers of metabolic syndrome in bipolar disorder patients, hypothesizing that lactate levels would be higher in those with metabolic syndrome.
  • The research involved a large cohort of 837 stable bipolar disorder patients and 237 others for validation, revealing that higher lactate levels correlated significantly with factors like triglycerides and blood pressure, indicating a strong association with metabolic syndrome.
  • The findings suggest that while lactate is a key biomarker related to metabolic syndrome in bipolar patients, circulating mitochondrial DNA levels do not show this same correlation, highlighting the potential for personalized treatment strategies based on these metabolite profiles.
View Article and Find Full Text PDF

Adherence to clinical practice guidelines for using electroconvulsive therapy in elderly depressive patients.

BMC Psychiatry

July 2024

French Society for Biological Psychiatry and Neuropsychopharmacology, Saint Germain en Laye, France.

Objectives: Electroconvulsive therapy (ECT) is one of the most effective treatments in mood disorders, mainly in major depressive episode (MDE) in the context of either unipolar (MDD) or bipolar disorder (BD). However, ECT remains a neglected and underused treatment. Older people are at high risk patients for the development of adverse drug reactions.

View Article and Find Full Text PDF

Aim: The anticholinergic properties of medications are associated with poorer cognitive performance in schizophrenia. Numerous scales have been developed to assess anticholinergic burden and yet, there is no consensus indicating which anticholinergic burden scale is more relevant for patients with schizophrenia. We aimed to identify valid scales for estimating the risk of iatrogenic cognitive impairment in schizophrenia.

View Article and Find Full Text PDF

Predictors of Functional Impairment in Bipolar Disorder: Results From 13 Cohorts From Seven Countries by the Global Bipolar Cohort Collaborative.

Focus (Am Psychiatr Publ)

October 2023

Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA (Burdick, Millett, Potter, Shanahan); University of Michigan, Ann Arbor, Michigan, USA (Yocum, Diaz-Byrd, McInnis); The Milken Institute, Washington, District of Columbia, USA (Altimus, Pham); NORMENT, Division of Mental Health and Addiction, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway (Andreassen, Lagerberg, Ueland); KG Jebsen Centre for Neurodevelopmental Disorders, University of Oslo, Oslo, Norway (Andreassen); Pôle de Psychiatrie, Centre Hospitalier Princesse Grace, Monaco, Monaco (Aubin); Pôle de Psychiatrie, Assistance Publique Hôpitaux de Marseille, Marseille, France; INT-UMR7289, CNRS Aix-Marseille Université, Marseille, France (Belzeaux); Deakin University, IMPACT - the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, Australia (Berk, Stuart, Williams, Wrobel); Orygen, The National Centre of Excellence in Youth Mental Health, Centre for Youth Mental Health, Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, The University of Melbourne, Melbourne, Australia (Berk, Wrobel); Mayo Clinic Department of Psychiatry & Psychology, Mayo Clinic, Rochester, Minnesota, USA (Biernacka, Frye); Mayo Clinic Department of Quantitative Health Sciences, Mayo Clinic, Rocester, MN, USA (Biernacka); Yale School of Medicine, New Haven, Connecticut, USA (Blumberg); Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK (Cleare, Strawbridge, Young); Université de Paris, INSERM UMR1266, AP-HP, Groupe Hospitalo-Universitaire AP-HP Nord, DMU ESPRIT, service de Psychiatrie et Addictologie, Hôpital Louis Mourier, Colombes, France (Dubertret); Université de Paris, AP-HP, Groupe Hospitalo-universitaire AP-HP Nord, DMU Neurosciences, Hôpital Fernand Widal, Département de Psychiatrie et de Médecine Addictologique, INSERM UMRS, Paris, France (Etain); University of California San Diego, La Jolla, CA, USA; Desert-Pacific Mental Illness Research Education and Clinical Center, VA San Diego Healthcare System, San Diego, California, USA (Eyler, Klaus); Division of Geriatric Psychiatry, McLean Hospital, Belmont, MA, USA (Forester); Harvard Medical School, Boston, Massachusetts, USA (Forester); Neuroscience Research Australia, Sydney, Australia (Fullerton); School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, Australia (Fullerton); Pôle de Psychiatrie Générale et Universitaire, Centre Hospitalier Charles Perrens, Bordeaux, France (Gard); Univ Paris Est Créteil, INSERM U955, IMRB, Translational Neuro-Psychiatry, Fondation FondaMental, Créteil, France; APHP, Hôpitaux Universitaires Henri Mondor, Département Médico-Universitaire de Psychiatrie et d'Addictologie, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), Créteil, France (Godin, Leboyer); Clinical Psychiatry Department, Treatment-Resistant Depression Fondamental Expert Center, EA 481 Neurosciences, Bourgogne Franche Comté University, Besançon, France (Haffen); Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain (Martinez-Aran, Sole, Vieta); SLM Lindner Center of HOPE, Mason, Ohio, USA; University of Cincinnati College of Medicine, Cincinnati, Ohio, USA (McElroy); School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, Australia (Mitchell); Department of Emergency Psychiatry and Acute Care, CHU Montpellier, IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France (Olie); Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA (Olorunfemi, Peters, Nierenberg); Service Hospitalo-Universitaire de psychiatrie d'adulte et d'addictologie, Centre Hospitalier de Versailles, INSERM UMR1018, DisAP-DevPsy-CESP, Université de Versailles Saint-Quentin-en-Yvelines, Université Paris-Saclay, Gif-sur-Yvette, France (Passerieux); Univ. Grenoble Alpes, CHU de Grenoble et des Alpes, Grenoble Institut des Neurosciences Inserm U 1216, Grenoble, France (Polosan); University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine, Cleveland, Ohio, USA (Sajatovic); CHU Clermont-Ferrand, Department of Psychiatry, University of Clermont Auvergne, UMR 6602 Institut Pascal, Clermont-Ferrand, France (Samalin); Université de Lorraine, Inserm U 1114, Pôle Hospitalo-Universitaire de Psychiatrie d'Adultes et d'Addictologie CPN, Laxou, France (Schwan); Department of Psychiatry, University of British Columbia, Vancouver, Canada (Torres, Yatham); Department of Psychology, University of Oslo, Oslo, Norway (Ueland); Barwon Health, Geelong, Victoria, Australia (Williams).

Objectives: Persistent functional impairment is common in bipolar disorder (BD) and is influenced by a number of demographic, clinical, and cognitive features. The goal of this project was to estimate and compare the influence of key factors on community function in multiple cohorts of well-characterized samples of individuals with BD.

Methods: Thirteen cohorts from 7 countries included = 5882 individuals with BD across multiple sites.

View Article and Find Full Text PDF

Background: Use of psychostimulants and relative drugs has increased worldwide in treatment of attention-deficit hyperactivity disorder (ADHD) in adolescents and adults. Recent studies suggest a potential association between use of psychostimulants and psychotic symptoms. The risk may not be the same between different psychostimulants.

View Article and Find Full Text PDF

Objective: The support of the personal recovery of people with lived experience of mental illness is a major issue in clinical practice. Thus, a valid instrument to assess personal recovery is needed. The present study aimed to validate the French translation of the 22-item Questionnaire about the Process of Recovery (QPR-Fr).

View Article and Find Full Text PDF

Factors associated with lamotrigine concentration/dose ratio in individuals with bipolar disorders.

Eur Neuropsychopharmacol

August 2023

Université Paris Cité Inserm UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006, Paris, France; Fondation FondaMental, 94010, Créteil, France; Centres Experts Trouble Bipolaire et Dépression Résistante, Assistance Publique des Hôpitaux de Paris, Hôpital Lariboisière-Fernand Widal, 75010 Paris, France.

Monitoring of lamotrigine levels is recommended in epilepsy. However, in bipolar disorders (BD), no study has described the therapeutic range in daily practice and factors being associated to it. We used retrospective data of individuals with BD, treated with lamotrigine, and included in the FondaMental Advanced Centers of Expertise for Bipolar Disorders cohort.

View Article and Find Full Text PDF

Withdrawal syndrome after antipsychotics discontinuation: an analysis of the WHO database of spontaneous reports (Vigibase) between 2000 and 2022.

Psychopharmacology (Berl)

June 2024

Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Faculty of Medicine and Toulouse University Hospital (CHU), 37 Allées Jules-Guesde 31000, Toulouse, France.

Article Synopsis
  • Withdrawal syndrome (WDS) may occur after stopping antipsychotic medications, potentially due to increased dopamine activity, especially with drugs closely binding to D2 receptors.* ! -
  • Analysis of pharmacovigilance data revealed that insomnia, anxiety, and depression were common withdrawal symptoms, with tiotixene showing the highest risk of WDS among antipsychotics studied.* ! -
  • The study found a weak correlation between the binding affinity of D2/5HT2A receptors and WDS risk, indicating that not all antipsychotics carry the same withdrawal risk, with some like chlorpromazine being safer.* !
View Article and Find Full Text PDF

French Society for Biological Psychiatry and Neuropsychopharmacology (AFPBN) guidelines for the management of patients with partially responsive depression and treatment-resistant depression: Update 2024.

Encephale

February 2024

French Society for Biological Psychiatry and Neuropsychopharmacology (AFPBN), Saint-Germain-en-Laye, France; Fondation FondaMental, Créteil, France; Department of Psychiatry, CHU of Clermont-Ferrand, University of Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal (UMR 6602), Clermont-Ferrand, France. Electronic address:

Introduction: The purpose of this update is to add newly approved nomenclatures and treatments as well as treatments yet to be approved in major depressive disorder, thus expanding the discussions on the integration of resistance factors into the clinical approach.

Methods: Unlike the first consensus guidelines based on the RAND/UCLA Appropriateness Method, the French Association for Biological Psychiatry and Neuropsychopharmacology (AFPBN) developed an update of these guidelines for the management of partially responsive depression (PRD) and treatment-resistant depression (TRD). The expert guidelines combine scientific evidence and expert clinicians' opinions to produce recommendations for PRD and TRD.

View Article and Find Full Text PDF

Regional differences in mortality risk and in attenuating or aggravating factors in schizophrenia: A systematic review and meta-analysis.

Eur Neuropsychopharmacol

March 2024

Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany; Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA; Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.

People with schizophrenia die prematurely, yet regional differences are unclear. PRISMA 2020-compliant systematic review/random-effects meta-analysis of cohort studies assessing mortality relative risk (RR) versus any control group, and moderators, in people with ICD/DSM-defined schizophrenia, comparing countries and continents. We conducted subgroup, meta-regression analyses, and quality assessment.

View Article and Find Full Text PDF

Two polygenic mouse models of major depressive disorders identify TMEM161B as a potential biomarker of disease in humans.

Neuropsychopharmacology

June 2024

Univ Paris Est Créteil, INSERM, IMRB, Translational Neuropsychiatry, F-94010, Créteil, France.

Treatments are only partially effective in major depressive disorders (MDD) but no biomarker exists to predict symptom improvement in patients. Animal models are essential tools in the development of antidepressant medications, but while recent genetic studies have demonstrated the polygenic contribution to MDD, current models are limited to either mimic the effect of a single gene or environmental factor. We developed in the past a model of depressive-like behaviors in mice (H/Rouen), using selective breeding based on behavioral reaction after an acute mild stress in the tail suspension test.

View Article and Find Full Text PDF

Structural and functional changes associated with functional/dissociative seizures: A review of the literature.

Epilepsy Behav

March 2024

Service de Psychiatrie et de Psychologie Médicale (Department of Psychiatry and Medical Psychology), Centre Expert Dépression Résistante FondaMental, CHU de Toulouse, Hôpital Purpan, ToNIC Toulouse NeuroImaging Centre, Université de Toulouse, INSERM, UPS, Toulouse, France. Electronic address:

Introduction: The term 'functional/dissociative seizures (FDS)' refers to a paroxysmal, transient clinical manifestation that may include motor, sensory, vegetative, psychological and cognitive signs, similar to the manifestations observed in epileptic seizures. In recent years, there has been an increase of literature in the field of brain imaging research on functional neurological disorders and, more specifically, on FDS. However, most of the studies have been carried out on limited samples.

View Article and Find Full Text PDF

Introduction: Metabolic syndrome (MetS) is a cluster of components including abdominal obesity, hyperglycemia, hypertension, and dyslipidemia. MetS is highly prevalent in individuals with bipolar disorders (BD) with an estimated global rate of 32.6%.

View Article and Find Full Text PDF

Drug-induced depressive symptoms: An update through the WHO pharmacovigilance database.

J Affect Disord

April 2024

Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital (CHU), Faculty of Medicine, Toulouse, France; CIC 1436, Team PEPSS (Pharmacologie En Population cohorteS et biobanqueS), Toulouse University Hospital, Toulouse, France. Electronic address:

Background: Depression is a highly incident condition and some drugs have been described as inducing or worsening depression. However, literature on this topic is rare and possibly outdated.

Methods: We performed disproportionality analyses using VigiBase®, the largest pharmacovigilance database worldwide to identify drugs associated with depression.

View Article and Find Full Text PDF

Transcranial direct current stimulation (tDCS) is used to modulate brain function, and can modulate motor and postural control. While the acute effect of tDCS is well documented on patients, little is still known whether tDCS can alter the motor control of healthy trained participants. This study aimed to assess the acute effect of tDCS on postural control of parkour practitioners, known for their good balance abilities and their neuromuscular specificities that make them good candidates for tDCS intervention.

View Article and Find Full Text PDF

Clinical and cognitive characteristics of subjects with schizophrenia and childhood attention-deficit/hyperactivity disorder: Results from the multicentric FACE-SZ cross-sectional dataset.

Schizophr Res

February 2024

Fondation Fondamental, Créteil, France; Université de Paris, INSERM UMR1266, Institute of Psychiatry and Neuroscience of Paris, France; AP-HP, Department of Psychiatry, Louis Mourier Hospital, Colombes, France.

Background: Childhood Attention-deficit/hyperactivity disorder (C-ADHD) is a neurodevelopmental disorder, associated with an increased risk of subsequent schizophrenia. The objective of the present study was to determine the prevalence of C-ADHD in schizophrenia and the clinical and cognitive characteristics associated with C-ADHD history in schizophrenia.

Methods: 569 subjects with schizophrenia (74 % men, mean age 30.

View Article and Find Full Text PDF